Across O O O O
the O O O O
industry, O O O O
biopharmaceutical O O O O
companies O O O O
are O O O O
[working O O O O
around O O O O
the O O O O
clock](https://phrma.org/coronavirus) O O O O
to O O O O
meet O O O O
the O O O O
demands O O O O
of O O O O
COVID-19 O O O O
vaccine O O O O
manufacturing. O O O O
Companies O O O O
are O O O O
working O O O O
to O O O O
source O O O O
needed O O O O
raw O O O O
materials O O O O
and O O O O
other O O O O
supplies O O O O
and O O O O
increasing O O O O
manufacturing O O O O
capacity O O O O
to O O O O
get O O O O
COVID-19 O O O O
vaccine O O O O
shots O O O O
in O O O O
as O O O O
many O O O O
arms O O O O
as O O O O
possible. O O O O
Even O O O O
prior O O O O
to O O O O
knowing O O O O
the O O O O
efficacy O O O O
of O O O O
particular O O O O
vaccine O O O O
candidates, O O O O
companies O O O O
have O O O O
proactively O O O O
been O O O O
seeking O O O O
to O O O O
increase O O O O
their O O O O
own O O O O
manufacturing O O O O
capabilities O O O O
as O O O O
well O O O O
as O O O O
collaborate O O O O
with O O O O
other O O O O
manufacturers O O O O
who O O O O
shared O O O O
available O O O O
capacity O O O O
to O O O O
support O O O O
efforts O O O O
to O O O O
increase O O O O
production. O O O O
These O O O O
partnerships O O O O
have O O O O
been O O O O
key O O O O
so O O O O
that O O O O
as O O O O
safety O O O O
and O O O O
effectiveness O O O O
data O O O O
were O O O O
compiled O O O O
and O O O O
vaccines O O O O
were O O O O
authorized O O O O
by O O O O
regulatory O O O O
agencies, O O O O
manufacturing O O O O
could O O O O
ramp O O O O
up O O O O
quickly. O O O O
Yet O O O O
even O O O O
after O O O O
laying O O O O
significant O O O O
groundwork, O O O O
global O O O O
vaccination O O O O
efforts O O O O
face O O O O
challenges O O O O
stemming O O O O
from O O O O
the O O O O
innate O O O O
and O O O O
unavoidable O O O O
complexities O O O O
within O O O O
the O O O O
manufacturing O O O O
scale O O O O
up O O O O
processes O O O O
for O O O O
vaccines. O O O O
To O O O O
overcome O O O O
these O O O O
hurdles, O O O O
biopharmaceutical O O O O
companies O O O O
have O O O O
established O O O O
partnerships O O O O
to O O O O
help O O O O
support O O O O
increased O O O O
manufacturing O O O O
output O O O O
and O O O O
speed O O O O
up O O O O
the O O O O
ability O O O O
to O O O O
fight O O O O
COVID-19 O O O O
as O O O O
distribution O O O O
capacity O O O O
is O O O O
expanded O O O O
around O O O O
the O O O O
globe. O O O O
Below, O O O O
I've O O O O
addressed O O O O
four O O O O
questions O O O O
that O O O O
provide O O O O
greater O O O O
context O O O O
to O O O O
these O O O O
efforts: O O O O
How Reason 5 O O
complex Reason 5 O O
is Reason 5 O O
COVID-19 Reason 5 O O
vaccine Reason 5 O O
manufacturing? Reason 5 O O
Manufacturing Reason 5 O O
vaccines Reason 5 O O
on Reason 5 O O
a Reason 5 O O
global Reason 5 O O
scale Reason 5 O O
is Reason 5 O O
a Reason 5 O O
highly Reason 5 O O
complex, Reason 5 O O
specialized Reason 5 O O
and Reason 5 O O
intensive Reason 5 O O
bio-process Reason 5 O O
given Reason 5 O O
that Reason 5 O O
COVID-19 Reason 5 O O
vaccines Reason 5 O O
are Reason 5 O O
complex Reason 5 O O
biologic Reason 5 O O
products. Reason 5 O O
The Reason 5 O O
two Reason 5 O O
vaccines Reason 5 O O
which Reason 5 O O
first Reason 5 O O
received Reason 5 O O
[emergency Reason 5 O O
use Reason 5 O O
authorizations](/Blog/understanding-the-emergency-use-authorization-process-for-covid-19-vaccines) Reason 5 O O
(EUAs) Reason 5 O O
from Reason 5 O O
the Reason 5 O O
U.S. Reason 5 O O
Food Reason 5 O O
and Reason 5 O O
Drug Reason 5 O O
Administration Reason 5 O O
(FDA) Reason 5 O O
rely Reason 5 O O
on Reason 5 O O
a Reason 5 O O
completely Reason 5 O O
new Reason 5 O O
approach Reason 5 O O
to Reason 5 O O
creating Reason 5 O O
vaccines: Reason 5 O O
mRNA Reason 5 O O
technology. Reason 5 O O
mRNA Reason 5 O O
technology Reason 5 O O
has Reason 5 O O
been Reason 5 O O
decades Reason 5 O O
in Reason 5 O O
the Reason 5 O O
making Reason 5 O O
with Reason 5 O O
new Reason 5 O O
technological Reason 5 O O
platforms Reason 5 O O
for Reason 5 O O
manufacturing Reason 5 O O
playing Reason 5 O O
a Reason 5 O O
pivotal Reason 5 O O
role Reason 5 O O
in Reason 5 O O
enabling Reason 5 O O
the Reason 5 O O
rapid Reason 5 O O
development Reason 5 O O
of Reason 5 O O
COVID-19 Reason 5 O O
vaccines. Reason 5 O O
As Reason 5 O O
additional Reason 5 O O
vaccines Reason 5 O O
are Reason 5 O O
authorized Reason 5 O O
such Reason 5 O O
as Reason 5 O O
[the Reason 5 O O
vaccine Reason 5 O O
granted Reason 5 O O
an Reason 5 O O
EUA Reason 5 O O
on Reason 5 O O
February Reason 5 O O
27](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine), Reason 5 O O
there Reason 5 O O
will Reason 5 O O
be Reason 5 O O
different Reason 5 O O
manufacturing Reason 5 O O
approaches Reason 5 O O
for Reason 5 O O
different Reason 5 O O
vaccines, Reason 5 O O
with Reason 5 O O
each Reason 5 O O
required Reason 5 O O
to Reason 5 O O
comply Reason 5 O O
with Reason 5 O O
strict Reason 5 O O
FDA-mandated Reason 5 O O
requirements. Reason 5 O O
Expectations Reason 5 O O
for Reason 5 O O
reviewing Reason 5 O O
any Reason 5 O O
manufacturing Reason 5 O O
changes Reason 5 O O
will Reason 5 O O
also Reason 5 O O
be Reason 5 O O
established Reason 5 O O
by Reason 5 O O
the Reason 5 O O
FDA Reason 5 O O
and Reason 5 O O
followed Reason 5 O O
by Reason 5 O O
manufacturers. Reason 5 O O
The Reason 5 O O
process Reason 5 O O
of Reason 5 O O
manufacturing Reason 5 O O
COVID-19 Reason 5 O O
vaccines Reason 5 O O
safely, Reason 5 O O
effectively Reason 5 O O
and Reason 5 O O
consistently Reason 5 O O
on Reason 5 O O
a Reason 5 O O
global Reason 5 O O
scale Reason 5 O O
is Reason 5 O O
incredibly Reason 5 O O
challenging. Reason 5 O O
Due Reason 5 O O
to Reason 5 O O
the Reason 5 O O
complex Reason 5 O O
vaccine Reason 5 O O
manufacturing Reason 5 O O
process, Reason 5 O O
it Reason 5 O O
is Reason 5 O O
misguided Reason 5 O O
to Reason 5 O O
assume Reason 5 O O
that Reason 5 O O
vaccine Reason 5 O O
manufacturing Reason 5 O O
production Reason 5 O O
can Reason 5 O O
be Reason 5 O O
turned Reason 5 O O
on Reason 5 O O
at Reason 5 O O
a Reason 5 O O
moments Reason 5 O O
notice. Reason 5 O O
This Reason 5 O O
has Reason 5 O O
[been Reason 5 O O
reinforced Reason 5 O O
by Reason 5 O O
noted Reason 5 O O
biopharmaceutical Reason 5 O O
researcher Reason 5 O O
Derrick Reason 5 O O
Lowe](https://blogs.sciencemag.org/pipeline/archives/2021/02/02/myths-of-vaccine-manufacturing). Reason 5 O O
PolitiFact Reason 5 O O
has Reason 5 O O
also Reason 5 O O
[described Reason 5 O O
the Reason 5 O O
misleading Reason 5 O O
claim](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.politifact.com%2Ffactchecks%2F2021%2Ffeb%2F09%2Ffacebook-posts%2Fcan-pfizer-and-moderna-end-pandemic-sharing-their-%2F&data=04%7C01%7C%7Cb9ac4a4156884e4768ae08d8d7666640%7C794a0e5bd96f4b71a78a4456c6b5486a%7C1%7C0%7C637496182109456822%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=UIOfwc0AJ0G1QD8fiBNrL8X86MNeR23EGNZs2mUo%2BX8%3D&reserved=0) Reason 5 O O
as Reason 5 O O
"mostly Reason 5 O O
because Reason 5 O O
it Reason 5 O O
"oversimplifies Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
manufacturing Reason 5 O O
process" Reason 5 O O
and Reason 5 O O
"ignores Reason 5 O O
critical Reason 5 O O
facts." Reason 5 O O
How O O O O
are O O O O
companies O O O O
and O O O O
other O O O O
stakeholders O O O O
working O O O O
collaboratively O O O O
to O O O O
increase O O O O
manufacturing? O O O O
Even O O O O
before O O O O
the O O O O
FDA O O O O
authorized O O O O
a O O O O
COVID-19 O O O O
vaccine, O O O O
biopharmaceutical O O O O
companies O O O O
were O O O O
scaling O O O O
up O O O O
manufacturing O O O O
capacity. O O O O
Companies O O O O
have O O O O
been O O O O
identifying O O O O
other O O O O
manufacturers O O O O
with O O O O
the O O O O
appropriate O O O O
expertise, O O O O
technical O O O O
capabilities O O O O
and O O O O
facilities, O O O O
and O O O O
they O O O O
have O O O O
entered O O O O
into O O O O
partnerships O O O O
and O O O O
agreements O O O O
to O O O O
further O O O O
speed O O O O
up O O O O
the O O O O
production O O O O
of O O O O
vaccines. O O O O
These O O O O
partnerships O O O O
are O O O O
being O O O O
undertaken O O O O
by O O O O
companies O O O O
together O O O O
with O O O O
knowledge O O O O
of O O O O
which O O O O
facilities O O O O
and O O O O
their O O O O
staff O O O O
can O O O O
help O O O O
produce O O O O
vaccine O O O O
candidates. O O O O
These O O O O
collaborations O O O O
are O O O O
done O O O O
with O O O O
specific O O O O
considerations O O O O
in O O O O
mind O O O O
and O O O O
are O O O O
highly O O O O
technical O O O O
in O O O O
nature, O O O O
often O O O O
focused O O O O
on O O O O
a O O O O
single O O O O
step O O O O
or O O O O
stage O O O O
of O O O O
the O O O O
overall O O O O
manufacturing O O O O
process. O O O O
Some O O O O
recent O O O O
examples O O O O
of O O O O
industry O O O O
manufacturing O O O O
commitments O O O O
include O O O O
[[i]](#_edn1): O O O O
- O O O O
GSK O O O O
[will O O O O
support](https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/) O O O O
the O O O O
manufacture O O O O
of O O O O
up O O O O
to O O O O
100 O O O O
million O O O O
doses O O O O
of O O O O
CureVac's O O O O
first O O O O
generation O O O O
COVID-19 O O O O
vaccine O O O O
candidate O O O O
CVnCoV O O O O
in O O O O
2021. O O O O
- O O O O
Merck O O O O
has O O O O
entered O O O O
[into O O O O
agreements](https://www.merck.com/news/merck-to-help-produce-johnson-barda-to-provide-merck-with-funding-to-expand-mercks-manufacturing-capacity-for-covid-19-vaccines-and-medicines/) O O O O
with O O O O
Janssen O O O O
Pharmaceuticals, O O O O
Inc., O O O O
one O O O O
of O O O O
the O O O O
Janssen O O O O
Pharmaceutical O O O O
Companies O O O O
of O O O O
Johnson O O O O
& O O O O
Johnson O O O O
(J&J), O O O O
to O O O O
support O O O O
the O O O O
manufacturing O O O O
and O O O O
supply O O O O
of O O O O
J&J's O O O O
SARS-CoV-2/COVID-19 O O O O
vaccine. O O O O
Merck O O O O
will O O O O
use O O O O
its O O O O
facilities O O O O
in O O O O
the O O O O
United O O O O
States O O O O
to O O O O
produce O O O O
drug O O O O
substance, O O O O
formulate O O O O
and O O O O
fill O O O O
vials O O O O
of O O O O
J&J's O O O O
vaccine. O O O O
- O O O O
[Novartis O O O O
announced](https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-provide-manufacturing-capacity-pfizer-biontech-covid-19-vaccine) O O O O
that O O O O
it O O O O
has O O O O
signed O O O O
an O O O O
initial O O O O
agreement O O O O
to O O O O
leverage O O O O
its O O O O
manufacturing O O O O
capacity O O O O
and O O O O
capabilities O O O O
in O O O O
order O O O O
to O O O O
address O O O O
the O O O O
COVID-19 O O O O
pandemic O O O O
by O O O O
supporting O O O O
the O O O O
production O O O O
of O O O O
the O O O O
Pfizer-BioNTech O O O O
COVID-19 O O O O
Vaccine. O O O O
Under O O O O
the O O O O
terms O O O O
of O O O O
the O O O O
contract O O O O
manufacturing O O O O
agreement, O O O O
Novartis O O O O
plans O O O O
to O O O O
take O O O O
bulk O O O O
mRNA O O O O
active O O O O
ingredient O O O O
from O O O O
BioNTech O O O O
and O O O O
fill O O O O
this O O O O
into O O O O
vials O O O O
under O O O O
aseptic O O O O
conditions O O O O
for O O O O
shipment O O O O
back O O O O
to O O O O
BioNTech O O O O
for O O O O
their O O O O
distribution O O O O
to O O O O
health O O O O
care O O O O
system O O O O
customers O O O O
around O O O O
the O O O O
world. O O O O
- O O O O
Sanofi O O O O
in O O O O
2021, O O O O
will O O O O
provide O O O O
support O O O O
to O O O O
manufacture O O O O
two O O O O
COVID-19 O O O O
vaccines O O O O
in O O O O
order O O O O
to O O O O
help O O O O
address O O O O
global O O O O
needs O O O O
due O O O O
to O O O O
the O O O O
pandemic: O O O O
[BioNTech's O O O O
COVID-19 O O O O
vaccine](https://www.sanofi.com/en/media-room/press-releases/2021/2021-01-27-07-30-00) O O O O
(co-developed O O O O
with O O O O
Pfizer) O O O O
will O O O O
be O O O O
manufactured O O O O
at O O O O
Sanofi's O O O O
production O O O O
facilities O O O O
in O O O O
Frankfurt, O O O O
Germany; O O O O
[Janssen's O O O O
(J&J)](https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-22-11-40-00-2179318) O O O O
COVID-19 O O O O
vaccine O O O O
will O O O O
be O O O O
manufactured O O O O
at O O O O
Sanofi's O O O O
vaccine O O O O
facility O O O O
in O O O O
Marcy O O O O
l'Etoile, O O O O
France. O O O O
- O O O O
Takeda O O O O
[announced](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A*2F*2Fnam12.safelinks.protection.outlook.com*2F*3Furl*3Dhttps%*3A*2F*2Furldefense.com*2Fv3*2F__https%3A*2F*2Fnam12.safelinks.protection.outlook.com*2F*3Furl*3Dhttps*3A%2F%2Furldefense.com*2Fv3*2F_________________ O O O O
*3Furl*3Dhttps*3A*2F*2Fwww.takeda.com*2Fnewsroom*2Fnewsreleases*2F2020*2Ftakeda-expands-covid-19-... O O O O
(Read Reason 4 O O
more) Reason 4 O O
